Breaking Finance News

A statement released earlier today by Jefferies & Co about INC Research (NDAQ:INCR) bumps the target price to $62.00

Jefferies & Co bumped up the target of INC Research (NDAQ:INCR) to $62.00 stating a potential upside of 0.04%.

Boasting a price of $59.75, INC Research (NDAQ:INCR) traded 0.29% higher on the day. With the last stock price close up -1.26% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. INC Research has recorded a 50-day average of $56.00 and a two hundred day average of $52.66. Volume of trade was up over the average, with 843,606 shares of INCR changing hands over the typical 769,166

Performance Chart

INC Research (NDAQ:INCR)

With a total market value of $0, INC Research has price-earnings ratio of 31.86 with a one year low of $40.65 and a one year high of $61.10 .

A total of 7 equity analysts have released a research note on INCR. Three equity analysts rating the company a strong buy, four equity analysts rating the company a buy, three equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $52.43.

More About INC Research (NDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.